Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine is a Conjugate Vaccine owned by GSK, and is involved in 11 clinical trials, of which 8 were completed, and 3 are ongoing.
MenABCWY stimulates the immune system to produce a specific type of bactericidal antibodies against the polysaccharides A, B, C, X, Y and W135. The therapeutic candidate stimulates the immune response against the capsular polysaccharides and alleviates the disease.
The revenue for Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine is expected to reach a total of $6.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine NPV Report.
Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine Overview
MenABCWY vaccine is under development for the prevention of meningococcal infections in adolescents. The therapeutic candidate is a conjugate vaccine, administered through intramuscular as suspension. It contains purified capsular polysaccharides A, B, C, Y and W135. The therapeutic candidate acts by stimulating the body's immune system.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.
Quick View – Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine
|Highest Development Stage|